Pierre Blanchard/X
May 4, 2025, 12:45
Pierre Blanchard Highlights SBRT as New Option for Small Oral Cavity Cancers
Pierre Blanchard, Radiation Oncology Clinical Section Chief at Gustave Roussy Cancer Institute, shared a post on X:
“SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03.
- Convenient.
- Fast.
- Similar outcomes than post op brachy.
Mostly VMAT homogeneous plans.”
Pierre Blanchard highlighted findings from the STEREOPOSTOP GORTEC 2017-03 study, reporting SBRT as a viable post-resection treatment for small oral cavity cancers.
The approach offers convenience, speed, and comparable outcomes to postoperative brachytherapy, with predominantly homogeneous VMAT plans.
More posts featuring Pierre Blanchard.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 17:02
Jun 13, 2025, 16:13
Jun 13, 2025, 15:08